Is there a delay in the antidepressant effect? A meta-analysis

Journal of Clinical Psychiatry

Volumn 66, Issue 2, 2005, Pages 148-158

  Posternak, Michael A ^a   Zimmerman, Mark ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; DOXEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIRTAZAPINE; NEFAZODONE; PAROXETINE; PLACEBO; SERTRALINE; VENLAFAXINE; ZIMELDINE;

CLINICAL TRIAL; DEPRESSION; DRUG EFFECT; HAMILTON SCALE; HUMAN; META ANALYSIS; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 14644401055     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v66n0201     Document Type: Review

References (144)

1. Kuhn R. Uber die behandlung depressiver zustande mit einem Iminodibenzylderivat. [Treatment of depressive states with an iminodibenzyl derivative (G 22355).] Schweiz Med Wochenschr 1957;87:1135-1140
2. Kuhn R. The treatment of depressive states with G 22355 (imipramine hydrochloride). Am J Psychiatry 1958;115:459-464
3. Pollack B. Clinical findings in the use of Tofranil in depressive and other psychiatric states. Am J Psychiatry 1959;116:312-317
4. Keup W, Apolito A, Olinger L, et al. Tofranil (imipramine) in the treatment of depressive states. J Nerv Ment Dis 1960;130:146-150
5. Angst J. Mechanisms of Action of Imipramine and Its Therapeutic Use. Bern, Switzerland: Stampfli and Cie; 1970
6. Hordern A. The antidepressant drugs. N Engl J Med 1965;272: 1159-1169
7. Klerman GL, Cole JO. Clinical pharmacology of imipramine and related antidepressant compounds. Pharmacol Rev 1965;17:101-141
8. Hollister LE. Tricyclic antidepressants (first of two parts). N Engl J Med 1978;299:1106-1109
9. Klerman GL, Hirschfeld RMA. The use of antidepressants in clinical practice. JAMA 1978;240:1403-1406
10. Angst J. Mechanisms of Action of Imipramine and Its Therapeutic Use. Bern, Switzerland: Stampfli and Cie; 1970
11. Montgomery SA. Are 2-week trials sufficient to indicate efficacy? Psychopharmacol Bull 1995;31:41-44
12. Post RM. Mood disorders: somatic treatment. In: Kaplan HI, Sadock BJ, eds. Comprehensive Textbook of Psychiatry. Baltimore, Md: Williams & Williams; 1995:1152-1178
13. Schatzberg AF, Cole JO, DeBattista C. Antidepressants, Manual of Clinical Psychopharmacology. Fourth Edition. Washington, DC: American Psychiatric Publishing; 2003:37-157
14. Hyman SE, Nestler EJ. The Molecular Foundations of Psychiatry. Washington, DC: American Psychiatric Press; 1993
15. Frazer A, Scott PA. Onset of action of antidepressant treatments: neuropharmacological aspects. In: Langer SZ, Brunello N, Racagni G, eds. Critical Issues in the Treatment of Affective Disorders. Basel, Switzerland: Karger; 1994:82-89
16. Mischoulon D. Why do antidepressants take so long to work? Am Soc Clin Psychopharmacology Progress Notes 1997:8:9-11
17. Quitkin FM, Rabkin JG, Ross D, et al. Duration of antidepressant drug treatment: what is an adequate trial? Arch Gen Psychiatry 1984; 41:238-245
18. Quitkin FM, Rabkin JG, Ross D, et al. Identification of true drug response to antidepressants: use of pattern analysis. Arch Gen Psychiatry 1984;41:782-786
19. Quitkin FM, Rabkin JD, Markowitz JM, et al. Use of pattern analysis to identify true drug response: a replication. Arch Gen Psychiatry 1987; 44:259-264
20. Quitkin FM, McGrath PJ, Rabkin JG, et al. Different types of placebo response in patients receiving antidepressants. Am J Psychiatry 1991; 148:197-203
21. Quitkin FM, Rabkin JG, Stewart JW, et al. Heterogeneity of clinical response during placebo treatment. Am J Psychiatry 1991;148:193-196
22. Quitkin FM, Stewart JW, McGrath PJ, et al. Loss of drug effects during continuation therapy. Am J Psychiatry 1993;150:562-565
23. Quitkin FM, Stewart JW, McGrath PJ, et al. Further evidence that a placebo response to antidepressants can be identified. Am J Psychiatry 1993;150:566-570
24. Stewart JW, Quitkin FM, McGrath PJ, et al. Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo. Arch Gen Psychiatry 1998;55:334-343
25. Winokur G. What to do? or what do we owe our residents. Biol Psychiatry 1980;15:599-611
26. Small JG, Milstein V, Kellams JJ, et al. Comparative onset of improvement in depressive symptomatology with drug treatment, electroconvulsive therapy, and placebo. J Clin Psychopharmacol 1981;1:62S-69S
27. Coryell W, Coppen A, Zeigler VE, et al. Early improvement as a predictor of response to amitriptyline and nortriptyline: a comparison of 2 patient samples. Psychol Med 1982;12:135-139
28. Katz MM, Koslow SH, Maas JW, et al. The timing, specificity and clinical prediction of tricyclic drug effects in depression. Psychol Med 1987;17:297-309
29. Nagayama J, Nagano K, Ikezaki A, et al. Prediction of efficacy of antidepressant by 1-week test therapy in depression. J Affect Disord 1991;23:213-216
30. Bowden CL, Schatzberg AF, Rosenbaum A, et al. Fluoxetine and desipramine in major depressive disorder. J Clin Psychopharmacol 1993;13:305-310
31. Nierenberg AA, McLean NE, Alpert JE, et al. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry 1995;152:1500-1503
32. Volz H-P, Muller H, Sturm Y, et al. Effect of initial treatment with antidepressants as a predictor of outcome after 8 weeks. Psychiatry Res 1995;58:107-115
33. Stassen HH, Angst J, Delini-Stula A. Fluoxetine versus moclobemide: cross-comparison between the time course of improvement. Pharmacopsychiatry 1999;32:56-60
34. Nierenberg AA, Farabaugh AH, Alpert JE, et al. Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatry 2000;157:1423-1428
35. Aberg-Wistedt A, Agren H, Ekselius L, et al. Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy. J Clin Psychopharmacol 2000;20:645-652
36. Szegedi A, Müller MJ, Anghelescu I, et al. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J Clin Psychiatry 2003;64:413-420
37. Moller HJ, Fischer G, von Zerssen D. Prediction of therapeutic response in acute treatment with antidepressants: results of empirical study involving 159 endogenous depressive inpatients. Eur Arch Psychiatry Neurol Sci 1987;236:349-357
38. Tollefson GD, Holman SL. How long to onset of antidepressant action: a meta-analysis of patients treated with fluoxetine or placebo. Int Clin Psychopharmacol 1994;9:245-250
39. Stassen JJ, Angst J, Delini-Stula A. Delayed onset of action of antidepressant drugs? survey of results of Zurich meta-analyses. Pharmacopsychiatry 1996;29:87-96
40. Walsh BT, Seidman SN, Sysko R, et al. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002;287:1840-1847
41. Rush AJ, Crismon ML, Toprac MG, et al. Consensus guidelines in the treatment of major depressive disorder. J Clin Psychiatry 1998; 59(suppl 20):73-84
42. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
43. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:56-62
44. Amsterdam JD, Case WG, Csanalosi E, et al. A double-blind comparative trial of zimelidine, amitriptyline, and placebo in patients with mixed anxiety and depression. Pharmacopsychiatry 1986;19:115-119
45. Amsterdam JD, Dunner DL, Fabre LF, et al. Double-blind, placebo-controlled, fixed dose trial of minaprine in patients with major depression. Pharmacopsychiatry 1989;22:137-143
46. Bakish D, Bradwejn J, Nair N, et al. A comparison of moclobemide, amitriptyline and placebo in depression: a Canadian multicentre study. Psychopharmacology (Berl) 1992;106:598-5101
47. Bremner JD. A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. J Clin Psychiatry 1995;56:519-525
48. Byerley WF, Reimherr FW, Wood DR, et al. Fluoxetine, a selective serotonin uptake inhibitor, for the treatment of outpatients with major depression. J Clin Psychopharmacol 1988;8:112-115
49. Chouinard G, Saxena BM, Nair NPV, et al. A Canadian multicenter placebo-controlled study of a fixed dose of brofaromine, a reversible selective MAO-A inhibitor, in the treatment of major depression. J Affect Disord 1994;32:105-114
50. Claghorn J, Gershon S, Goldstein BJ, et al. A double-blind evaluation of zimelidine in comparison to placebo and amitriptyline in patients with major depressive disorder. Prog Neuropsychophaimacol Biol Psychiatry 1983;7:367-382
51. Claghorn JL, Kiev A, Rickels K, et al. Paroxetine versus placebo: a double-blind comparison in depressed patients. J Clin Psychiatry 1992;53:434-438
52. Claghorn JL, Lesem MD. A double-blind placebo-controlled study of Org 3770 in depressed outpatients. J Affect Disord 1995;34:165-171
53. Claghorn JL, Earl CQ, Walczak DD, et al. Fluvoxamine maleate in the treatment of depression: a single-center, double-blind, placebo-controlled comparison with imipramine in outpatients. J Clin Psychopharmacol 1996;16:113-120
54. Cohn JB, Wilcox C. A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder. J Clin Psychiatry 1985;46(3, sec2):26-31
55. Cohn JB, Collins G, Ashbrook E, et al. A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol 1989;4:313-322
56. Cohn CK, Robinson DS, Roberts DL, et al. Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression. J Clin Psychiatry 1996;57(suppl 2): 15-18
57. Conti L, Dell'Osso L. Clinical predictors of response to fluvoxamine, imipramine, and placebo. New Trends in Experimental and Clinical Psychiatry 1989;4:221-229
58. Cunningham LA, Borison RL, Carman JS, et al. A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol 1994;14:99-106
59. Cunningham LA. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Ann Clin Psychiatry 1997;9:157-164
60. Davidson JRT, Giller EL, Zisook S, et al. An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology. Arch Gen Psychiatry 1988;45:120-127
61. Dominguez RA, Goldstein BJ, Jacobson AF, et al. A double-blind placebo-controlled study of fluvoxamine and imipramine in depression. J Clin Psychiatry 1985;46:84-87
62. Dunlop SR, Dornseif BE, Wernick JF, et al. Pattern analysis shows beneficial effect of fluoxetine treatment in mild depression. Psychopharmacol Bull 1990;26:173-180
63. Fabre LF, Abuzzahab FS, Amin M, et al. Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Biol Psychiatry 1995;38:592-602
64. Feighner JP, Aden GC, Fabre LF, et al. Comparison of alprazolam, imipramine, and placebo in the treatment of depression. JAMA 1983;249:3057-3064
65. Feighner JP, Boyer WF. Paroxetine in the treatment of depression: a comparison with imipramine and placebo. Acta Psychiatr Scand 1989;80(suppl 350):125-129
66. Ferguson JM, Mendels J, Manowitz NR. Dothiepin versus doxepin in major depression: results of a multicenter, placebo-controlled trial. J Clin Psychiatry 1994;55:258-263
67. Fontaine R, Ontiveros A, Elie R, et al. A double-blind comparison of nefazodone, imipramine, and placebo in major depression. J Clin Psychiatry 1994;55:234-241
68. Gelenberg AJ, Wojcik JD, Falk WE, et al. Clovoxamine in the treatment of depressed outpatients: a double-blind, parallel-group comparison against amitriptyline and placebo. Compr Psychiatry 1990;31:307-314
69. Giller E, Bialos D, Harkness L, et al. Assessing treatment response to the monoamine oxidase inhibitor isocarboxazid. J Clin Psychiatry 1984;45 (7, sec 2):44-48
70. Halikas JA. Org 3770 (mirtazapine) versus trazodone: a placebo controlled trial in depressed elderly patients. Hum Psychopharmacol 1995;10:5125-5133
71. Heiligenstein JH, Tollefson GD, Paries DE. Response patterns of depressed outpatients with and without melancholia: a double-blind, placebo-controlled trial of fluoxetine versus placebo. J Affect Disord 1994;30:163-173
72. Hormazabal L, Omer LMO, Ismail S. Cianopramine and amitriptyline in the treatment of depressed patients: a placebo-controlled study. Psychopharmacology (Berl) 1985;86:205-208
73. Itil TM, Shrivastava RK, Mukherhee S, et al. A double-blind placebo-controlled study of fluvoxamine and imipramine in out-patients with primary depression. Br J Clin Pharmacol 1983;15:433S-438S
74. Khan A, Dager SR, Cohen S, et al. Chronicity of depressive episode in relation to antidepressant-placebo response. Neuropsychopharmacology 1991;4:125-130
75. Khan MC. A randomised, double-blind, placebo-controlled, 5-weeks' study of Org 3770 (mirtazapine) in major depression. Hum Psychopharmacol 1995;10:S119-S124
76. Laakman G, Faltermaier-Temizel M, Bossert-Zaudig S, et al. Treatment of depressive outpatients with lorazepam, alprazolam, amitriptyline and placebo. Psychopharmacology (Berl) 1995;120:109-115
77. Lapierre YD, Silverstone P, Reesal RT, et al. A Canadian multicenter study of three fixed doses of controlled-release ipsapirone in outpatients with moderate to severe depression. J Clin Psychopharmacol 1998;18: 268-273
78. Lineberry CG, Johnston A, Raymond RN, et al. A fixed-dose (300 mg) efficacy study of bupropion and placebo in depressed outpatients. J Clin Psychiatry 1990;51:194-199
79. Lipman RS, Covi L, Rickels K, et al. Imipramine and chlordiazepoxide in depressive and anxiety disorders: efficacy in depressed outpatients. Arch Gen Psychiatry 1986;43:68-77
80. Lydiard RB, Stahl SM, Hertzman M, et al. A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression. J Clin Psychiatry 1997;58:484-491
81. Mendels J, Schless AP. Comparative efficacy of alprazolam, imipramine, and placebo administered once a day in treating depressed patients. J Clin Psychiatry 1986;47:357-361
82. Mendels J, Johnston R, Mattes J, et al. Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study. Psychopharmacol Bull 1993;29:169-174
83. Merideth CH, Feighner JP. A double-blind, controlled evaluation of zimelidine, imipramine and placebo in patients with primary affective disorders. Acta Psychiatr Scand 1983;68(suppl 308):70-79
84. Muijen M, Roy D, Silverstone T, et al. A comparative clinical trial of fluoxetine, mianserin and placebo in depressed outpatients. Acta Psychiatr Scand 1988;78:384-390
85. Nair NPV, Amin M, Holm P, et al. Moclobemide and nortriptyline in elderly depressed patients: a randomized, multicenter trial against placebo. J Affect Disord 1995;33:1-9
86. Ose E, Holm P. Moclobemide and placebo in mild major depression: a double-blind randomized trial. Psychopharmacology (Berl) 1992;106 (suppl 1A):S114-S115
87. Peselow ED, Stanley M, Filippi AM, et al. The predictive value of the dexamethasone suppression test: a placebo-controlled study. Br J Psychiatry 1989;155:667-672
88. Reimherr FW, Wood DR, Byerley B, et al. Characteristics of responders to fluoxetine. Psychopharmacol Bull 1984;20:70-72
89. Reimherr FW, Chouinard G, Cohn CK, et al. Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled. multicenter comparison study in outpatients with major depression. J Clin Psychiatry 1990;51(12, suppl):18-27
90. Rickels K, Weise CC, Sandler K, et al. Nomifensine, imipramine and placebo in depressed outpatients. Int Pharmacopsychiatry 1982;17 (suppl 1):73-88
91. Rickels K, Feighner JP, Smith WT. Alprazolam, amitriptyline, doxepin, and placebo in the treatment of depression. Arch Gen Psychiatry 1985; 42:134-141
92. Rickels K, Chung HR, Casanalosi IB, et al. Alprazolam, diazepam, imipramine, and placebo in outpatients with major depression. Arch Gen Psychiatry 1987;44:862-866
93. Rickels K, London J, Rox I, et al. Adinazolam, diazepam, imipramine, and placebo in major depressive disorder: a controlled study. Pharmacopsychiatry 1991;24:127-131
94. Rickels K, Robinson DS, Schweizer E, et al. Nefazodone: aspects of efficacy. J Clin Psychiatry 1995;56(suppl 6):43-46
95. Rickels K, Derivan A, Kunz N, et al. Zalospirone in major depression: a placebo-controlled multicenter study. J Clin Psychopharmacol 1996; 16:212-217
96. 1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression. J Clin Psychopharmacol 1990;10:67S-76S
97. Rudolph RL, Fabre LF, Feighner JP, et al. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry 1998;59:116-122
98. Rudolph RL, Feiger AD. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord 1999; 56:171-181
99. Ruther E, Degner D, Munzel U, et al. Antidepressant action of sulpiride: results of a placebo-controlled double-blind trial. Pharmacopsychiatry 1999;32:127-132
100. Schatzberg AF. Clinical efficacy of reboxetine in major depression. J Clin Psychiatr 2000;61 (suppl 10):31-38
101. Schrader E, Meier B, Brattstroem A. Hypericum treatment of mild-moderate depression in a placebo-controlled study: a prospective, double-blind, randomized, placebo-controlled, multicentre study. Hum Psychopharmacol 1998;13:163-169
102. Schweizer E, Feighner J, Mandos LA, et al. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry 1994;55:104-108
103. Schweizer E, Rickels K, Hassman H, et al. Buspirone and imipramine for the treatment of major depression in the elderly. J Clin Psychiatry 1998;59:175-183
104. Silverstone PH, Ravindran A, for the Venlafaxine XR 360 Study Group. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. J Clin Psychiatry I999;60:22-28
105. Smith WT, Glaudin V, Panagides J, et al. Mirtazapine vs amitriptyline vs placebo in the treatment of major depressive disorder. Psychopharmacol Bull 1990;20:191-196
106. Stahl SM. Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline. Biol Psychiatry 2000;48: 894-901
107. Stark P, Hardison CD. A review of multicenter controlled studies of fluoxetine vs imipramine and placebo in outpatients with major depressive disorder. J Clin Psychiatry 1985;46(3, sec 2):53-58
108. Stewart JW, McGrath PJ, Leibowitz MR, et al. Treatment outcome validation of DSM-III depressive subtypes: clinical usefulness in outpatients with mild to moderate depression. Arch Gen Psychiatry 1985;42:1148-1153
109. Stewart JW, McGrath PJ, Quitkin FM, et al. Relevance of DSM-III depressive subtype and chronicity of antidepressant efficacy in atypical depression: differential response to phenelzine, imipramine, and placebo. Arch Gen Psychiatry 1989;46:1080-1087
110. Thase ME, for the Venlafaxine XR 209 Study Group. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in out-patients with major depression. J Clin Psychiatry 1997;58:393-398
111. Thompson C. Management of depression in real-life settings: knowledge gained from large-scale clinical trials. Int Clin Psychopharmacol 1994;9(suppl 3):21-25
112. Tollefson GD, Holman SL. Analysis of the Hamilton Depression Rating Scale factors from a double-blind, placebo-controlled trial of fluoxetine in geriatric major depression. Int Clin Psychopharmacol 1993;8:253-259
113. Versiani M, Oggero U, Alterwain P, et al. A double-blind comparative trial of moclobemide v imipramine and placebo in major depressive episodes. Br J Psychiatry 1989;155(suppl 6):72-77
114. Wernicke JF, Dunlop SR, Dornseif BE, et al. Fixed-dose fluoxetine therapy for depression. Psychopharmacol Bull 1987;23:164-168
115. White K, Razani J, Cadow B, et al. Tranylcypromine vs nortriptyline vs placebo in depressed outpatients: a controlled trial. Psychopharmacology (Berl) 1984;82:258-262
116. Wilcox CS, Cohn JB, Katz BB, et al. A double-blind, placebo-controlled study comparing mianserin and amitriptyline in moderately depressed outpatients. Int Clin Psychopharmacol 1994;9:271-279
117. Wilcox CS, Ferguson JM, Dale JL, et al. A double-blind trial of low- and high-dose ranges of gepirone-ER compared with placebo in the treatment of depressed outpatients. Psychopharmacol Bull 1996;32:335-342
118. UK Moclobemide Study Group. A multicentre comparative trial of moclobemide, imipramine and placebo in major depressive disorder. Int Clin Psychopharmacol 1994;9:109-113
119. Mendels J, Reimherr F, Marcus RN, et al. A double-blind, placebo-controlled trial of two dose ranges of nefazodone in the treatment of depressed outpatients. J Clin Psychiatry 1995;56(suppl 6):30-36
120. Georgotas A, McCue RE, Friedman E, et al. Response of depressive symptoms to nortriptyline, phenelzine and placebo. Br J Psychiatry 1987;151:102-106
121. Georgotas A, McCue RE, Cooper TB, et al. Factors affecting the delay of antidepressant effect in responders to nortriptyline and phenelzine. Psychiatry Res 1989;28:1-9
122. Moller HJ, Muller H, Volz JP. How to assess the onset of antidepressant effect: comparison of global ratings and findings based on depression scales. Pharmacopsychiatry 1996;29:57-62
123. Cohn JB, Wilcox CS. Paroxetine in major depression: a double-blind trial with imipramine and placebo. J Clin Psychiatry 1992;53 (2, suppl):52-56
124. Fabre LF. A 6-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients. J Clin Psychiatry 1992;53 (2, suppl):40-43
125. Khan A, Upton V, Rudolph RL, et al. The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. J Clin Psychopharmacol 1998;18:19-25
126. Kiev A. A double-blind, placebo-controlled study of paroxetine in depressed outpatients. J Clin Psychiatry 1992;53(2, suppl):27-29
127. Rickels K, Amsterdam J, Clary C, et al. The efficacy and safety of paroxetine compared with placebo in outpatients with major depression. J Clin Psychiatry 1992;53(2, suppl):30-32
128. Shrivastava RK, Shrivastava SP, Overweg N, et al. A double-blind comparison of paroxetine, imipramine, and placebo in major depression. J Clin Psychiatry 1992;53(2, suppl):48-51
129. Smith WT, Glaudin V. A placebo-controlled trial of paroxetine in the treatment of major depression. J Clin Psychiatry 1992;53(2, suppl): 36-39
130. Mulder RT, Joyce PR, Frampton C. Relationships among measures of treatment outcome in depressed patients. J Affect Disord 2003;76: 127-135
131. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991;48: 851-855
132. Nierenberg AA, DeCecco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry 2001;62(suppl 16):5-9
133. Stassen HH, Delini-Stula A, Angst J. Time course of improvement under antidepressant treatment: a survival-analytical approach. Eur Neuropsychopharmacol 1993;3:127-135
134. Stassen HH, Angst J, Delini-Stula A. Severity at baseline and onset of improvement in depression: meta-analysis of imipramine and moclobemide versus placebo. Eur Psychiatry 1994;9:129-136
135. Nobler MS, Sackeim HA, Moeller JR, et al. Quantifying the speed of symptomatic improvement with electroconvulsive therapy: comparison of alternative statistical methods. Convuls Ther 1997;13:208-221
136. Laska EM, Siegel C. Characterizing onset in psychopharmacological clinical trials. Psychopharmacol Bull 1995;31:29-35
137. Agid O, Kapur S, Arenovich T, et al. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 2003;60:1228-1235
138. McGrath PJ, Stewart JW, Petkova E, et al. Predictors of relapse during fluoxetine continuation or maintenance treatment of major depression. J Clin Psychiatry 2000;61:518-524
139. Gilbody SM. Publication bias and the integrity of psychiatry research. Psychol Med 2000;30:253-258
140. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-241
141. Quitkin FM, Petkova E, McGrath PJ, et al. When should a trial of fluoxetine for major depression be declared failed? Am J Psychiatry 2003;160:734-740
142. Mayberg JS, Silva JA, Brannan SK, et al. The functional neuroanatomy of the placebo effect. Am J Psychiatry 2002;159:728-737
143. Leuchter AF, Cook IA, Witte EA, et al. Changes in brain function of depressed subjects during treatment with placebo. Am J Psychiatry 2002;159:122-129
144. Harmer CJ, Hill SA, Taylor MJ, et al. Toward a neuropsychological theory of antidepressant drug action: increase in positive emotional bias after potentiation of norepinephrine activity. Am J Psychiatry 2003;160:990-992